Novo

Novo Shares Rise After Exiting Metsera Takeover Battle

We’re seeing a clear bump in Novo Nordisk’s share price after the company pulled out of the takeover fight for Metsera. This move grabbed attention because the stakes were high. Novo is a big player in the obesity and diabetes drug market. Metsera is a rising biotech with strong promise in weight‑loss treatments. By stepping away,…

Novo

Novo News: Boardroom Rift Expected to Refocus Drugmaker on U.S. Growth Strategy

We’ve reached a turning point at Novo. The Danish drugmaker known for its blockbuster weight-loss treatment has seen a boardroom shake-up: its chair and several independent directors are stepping down.This is more than just a governance drama. It’s a signal of a strategic reset. Novo’s biggest shareholder has pushed for change and now wants the…